These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31052524)

  • 61. Sestrin2 in cancer: a foe or a friend?
    Ala M
    Biomark Res; 2022 May; 10(1):29. PubMed ID: 35527284
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Structural and Drug Targeting Insights on Mutant p53.
    Gomes AS; Ramos H; Inga A; Sousa E; Saraiva L
    Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283062
    [TBL] [Abstract][Full Text] [Related]  

  • 63. NRF2 and STAT3: friends or foes in carcinogenesis?
    Arena A; Romeo MA; Benedetti R; Gilardini Montani MS; Santarelli R; Gonnella R; D'Orazi G; Cirone M
    Discov Oncol; 2023 Mar; 14(1):37. PubMed ID: 37000324
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Mutant p53, Stabilized by Its Interplay with HSP90, Activates a Positive Feed-Back Loop Between NRF2 and p62 that Induces Chemo-Resistance to Apigenin in Pancreatic Cancer Cells.
    Gilardini Montani MS; Cecere N; Granato M; Romeo MA; Falcinelli L; Ciciarelli U; D'Orazi G; Faggioni A; Cirone M
    Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31121848
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Interconnected Adaptive Responses: A Way Out for Cancer Cells to Avoid Cellular Demise.
    D'Orazi G; Cirone M
    Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681760
    [TBL] [Abstract][Full Text] [Related]  

  • 66. STAT3 and mutp53 Engage a Positive Feedback Loop Involving HSP90 and the Mevalonate Pathway.
    Romeo MA; Gilardini Montani MS; Benedetti R; Santarelli R; D'Orazi G; Cirone M
    Front Oncol; 2020; 10():1102. PubMed ID: 32754441
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Alternative Mechanisms of p53 Action During the Unfolded Protein Response.
    Fusée LTS; Marín M; Fåhraeus R; López I
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32050651
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.
    Stein Y; Rotter V; Aloni-Grinstein R
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817996
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mutant p53 in Cancer Progression and Targeted Therapies.
    Zhu G; Pan C; Bei JX; Li B; Liang C; Xu Y; Fu X
    Front Oncol; 2020; 10():595187. PubMed ID: 33240819
    [No Abstract]   [Full Text] [Related]  

  • 70. Modulatory Effects of Chalcone Thio-Derivatives on NF-κB and STAT3 Signaling Pathways in Hepatocellular Carcinoma Cells: A Study on Selected Active Compounds.
    Papierska K; Judasz E; Tonińska W; Kubicki M; Krajka-Kuźniak V
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39409068
    [TBL] [Abstract][Full Text] [Related]  

  • 71. ATF6 supports lysosomal function in tumor cells to enable ER stress-activated macroautophagy and CMA: impact on mutant TP53 expression.
    Benedetti R; Romeo MA; Arena A; Gilardini Montani MS; D'Orazi G; Cirone M
    Autophagy; 2024 Aug; 20(8):1854-1867. PubMed ID: 38566314
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization.
    Mendoza RP; Chen-Yost HI; Wanjari P; Wang P; Symes E; Johnson DN; Reeves W; Mueller J; Antic T; Biernacka A
    Cancer Med; 2024 Jan; 13(1):e6873. PubMed ID: 38164123
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Wild-type and mutant p53 in cancer-related ferroptosis. A matter of stress management?
    Corazzari M; Collavin L
    Front Genet; 2023; 14():1148192. PubMed ID: 37021009
    [TBL] [Abstract][Full Text] [Related]  

  • 74. p53 Function and Dysfunction in Human Health and Diseases.
    D'Orazi G
    Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979441
    [TBL] [Abstract][Full Text] [Related]  

  • 75. NRF2 and Bip Interconnection Mediates Resistance to the Organometallic Ruthenium-Cymene Bisdemethoxycurcumin Complex Cytotoxicity in Colon Cancer Cells.
    Garufi A; Pettinari R; Marchetti F; Cirone M; D'Orazi G
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831129
    [TBL] [Abstract][Full Text] [Related]  

  • 76. NRF2 in Cancer: Cross-Talk with Oncogenic Pathways and Involvement in Gammaherpesvirus-Driven Carcinogenesis.
    Cirone M; D'Orazi G
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614036
    [TBL] [Abstract][Full Text] [Related]  

  • 77. c-Myc Sustains Pancreatic Cancer Cell Survival and mutp53 Stability through the Mevalonate Pathway.
    Romeo MA; Gilardini Montani MS; Arena A; Benedetti R; D'Orazi G; Cirone M
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289751
    [TBL] [Abstract][Full Text] [Related]  

  • 78. DNA damage response signaling: A common link between cancer and cardiovascular diseases.
    Nikfarjam S; Singh KK
    Cancer Med; 2023 Feb; 12(4):4380-4404. PubMed ID: 36156462
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?
    Duffy MJ; Tang M; Rajaram S; O'Grady S; Crown J
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139658
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.